Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation

Agrawal, A.; Houghton, Lesley A.; Morris, Julie; Reilly, Brian; Guyonnet, Denis; Feuillerat, N. Goupil; Schlumberger, Armelle; Jakob, Stefan; Whorwell, Peter J.

doi:10.1111/j.1365-2036.2008.03853.x

Cited by 277 publications

(267 citation statements)

References 58 publications

Supporting

Mentioning

250

Contrasting

Unclassified

Order By: Relevance

“…Second, these anaerobic bacterias produce organic acid due to fermented sugar, make the PH value decreased and stimulate peristalsis to improve the intestinal fermentation process. Finally changed the microenvironment, and feces easy to be excreted (Abrams et al, 1967;Agrawal et al, 2009). …”

Section: Efficacy Of Bifidobacterium Tetragenous Viable Bacteria Tablmentioning

confidence: 99%

“…After cancer patients were treated by chemotherapy, some factors acted in vivo destroyed the intestinal microorganisms of cancer patients (De Paula et al, 2008;Blokhina et al, 2011;Zhan et al, 2012). The number of bifidobacteriums and other anaerobic bacteria drops, oligosaccharides accumulated in the intestine due to the short of bifidobacteriu (Agrawal et al, 2009;Lu et al, 2013). And the symptoms, eg., abdominal distension, abdominal pain, defecation discomfort, etc.…”

Section: Efficacy Of Bifidobacterium Tetragenous Viable Bactermentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation

Liu¹,

Huang²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To investigate the efficacy and side effects of Bifidobacterium tetragenous viable bacteria tablets in treating cancer patients with functional constipation during chemotherapy. Methods: A consecutive cohort of 100 cancer patients with functional constipation were divided into two equal groups: patients in the experimental group were given Bifidobacterium tetragenous viable bacteria tablets combined with chemotherapy, while patients in the control group received chemotherapy alone. After 4 weeks, the efficacy and side effects in treating functional constipation were evaluated. Results: Constipation in 48 patients in experimental group was controlled (9 returned to normal), with a total response rate of 96%, and 1 patient reported diarrhea (2%). In contrast only 16 patients in the control group demonstrated improvement and 34 were still constipated after chemotherapy, with a response rate of 32%. The difference in response rate was statistically significant (P <0.05). Conclusion: This study suggested that Bifidobacterium tetragenous viable bacteria tablets are effective and safe in treating cancer patients with functional constipation during chemotherapy.

show abstract

Section: Efficacy Of Bifidobacterium Tetragenous Viable Bacteria Tablmentioning

confidence: 99%

Section: Efficacy Of Bifidobacterium Tetragenous Viable Bactermentioning

confidence: 99%

Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation

Liu¹,

Huang²

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Agrawal et al reported that it was necessary to select an organism or a mixture of probiotics that exhibit the properties most suitable for the particular expected health benefit or physiological effect. 15 In a study by Choi SC, et al it was observed that probiotic fermented milk containing dietary fiber was more effective particularly in those patients with the constipation-predominant IBS. 16 The said study confirmed the available evidence that fiber appears to play a role in the management of patients with IBS, especially if constipation is the primary concern.…”

Section: -14mentioning

confidence: 99%

Combination of bulk laxative along with probiotics and prebiotics in the management of irritable bowel syndrome with constipation: A safe & effective option

Faruqui¹,

Jamaiwar²,

Sharma³

2017

Asian J Med Sci

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is a common and relapsing functional bowel disorder. This disease has a substantial global burden and is associated with significant disability and high costs that adversely affects the health related quality of life of large population worldwide. Aims and Objective: We studied the efficacy and tolerability of bulk laxative plus probiotic and prebiotic in the treatment of constipation associated IBS (IBS-C) in Indian patients. Materials and Methods: Eighty patients with symptoms of IBS-C were enrolled in a post-marketing surveillance, multicentre, open label, non-randomized, noncomparative study where EVAQ-P -combination of fiber (psylliun husk/Ispaghula, probiotic and prebiotic) was given BID for 6 weeks. The symptoms were assessed at baseline, and after completion of 2, 4 and 6 weeks of therapy. Results: Results showed a significant trend (p < 0.0001) of improvement from week 2 for abdominal pain, abdominal fullness, defecation frequency, straining during defecation, constipation and subject global assessment of relief (SGA). Approximately 6% patients showed flatulence (mild) as a treatment emergent side effect. Conclusion: Combination of ispaghula along with a blend of probiotics and prebiotic twice daily for 6 weeks is efficacious, safe, and well-tolerated in IBS-C patients.

show abstract

“…Bifidobacterium lactis DN-173 010 (Activia ® , Dannon, White Plains, NY) was shown to be efficacious in a female IBS-C population [78] and a healthy population with digestive symptoms [79,80]. A randomized, double-blind, controlled study examined the efficacy of fermented milk-containing B lactis DN-173 010 administered twice daily for 4 weeks in females with IBS-C (n = 34) who experienced bloating at least twice weekly [78].…”

Section: Bifidobacterium Lactis Dn-173 010mentioning

confidence: 99%

“…A randomized, double-blind, controlled study examined the efficacy of fermented milk-containing B lactis DN-173 010 administered twice daily for 4 weeks in females with IBS-C (n = 34) who experienced bloating at least twice weekly [78]. Compared with patients who received a control solution, patients who received B lactis had an improvement from baseline in median percentage change of maximal abdominal distension (P = 0.02), decreases in orocecal (P = 0.049) and colonic (P = 0.03) transit times, and reduced intensity of IBSrelated abdominal pain/discomfort (P = 0.04) and global IBS symptoms (P = 0.03) after 4 weeks of treatment.…”

Section: Bifidobacterium Lactis Dn-173 010mentioning

confidence: 99%

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Harris

Baffy

2017

Postgraduate Medicine

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS), which is characterized by recurrent abdominal pain and disordered bowel habits, is one of the most common functional bowel disorders. IBS is a substantial burden on both patient health-related quality of life and healthcare costs. Several pathophysiologic mechanisms have been postulated for the occurrence of IBS, including altered gastrointestinal motility, visceral hypersensitivity, changes in gut permeability, immune activation, gut-brain dysregulation, central nervous system dysfunction, and changes in the gut microbiota. Of note, both qualitative and quantitative differences have been observed in the gut microbiota of a population with IBS versus a healthy population. Because of the substantial interest in the gut microbiota and its role as a therapeutic target in IBS, this article provides an overview of specific interventions with the potential to modulate the gut microbiota in IBS, including elimination diets, prebiotics, probiotics, synbiotics, and nonsystemic antibiotics. Although probiotics and synbiotics are generally well tolerated, differences in the composition and concentration of different bacterial species and inclusion or exclusion of prebiotic components varies widely across studies and has prevented strong recommendations on their use in IBS. For nonsystemic antibiotics, rifaximin is indicated in the United States for the treatment of IBS with diarrhea in adults and has been shown to be efficacious and well tolerated in well-designed clinical trials. Overall, more consistent evidence is needed regarding the efficacy and safety of elimination diets, prebiotics, probiotics, and synbiotics for the treatment of patients with IBS. Furthermore, additional well-designed studies are needed that examine alterations in the gut microbiota that occur with these interventions and their potential associations with clinical symptoms of IBS. ARTICLE HISTORY

show abstract

Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation

Abstract: SUMMARY BackgroundA sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit.

Cited by 277 publications

References 58 publications

Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation

Efficacy of Bifidobacterium Tetragenous Viable Bacteria Tablets for Cancer Patients with Functional Constipation

Combination of bulk laxative along with probiotics and prebiotics in the management of irritable bowel syndrome with constipation: A safe & effective option

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Contact Info

Product

Resources

About